Replies to post #170599 on Biotech Values

[DewDiligence]

If acquired Teva's [national] identity would disappear.

I don’t think it’s that simple. Teva has certain requirements in its corporate charter that might be hard to undo, and the federal government of Israel can be expected to vigorously oppose any buyout by a foreign firm.

Teva's problem is simple, it is no longer a low cost producer of generic drugs.

Respectfully disagree. If Teva had never had the fortune of gaining the rights to Copaxone, it probably wouldn’t be undergoing an upheaval now. All of Teva’s current problems can be traced, directly or indirectly, to the impending loss of one of the most profitable drug franchises of all time.